Ovarian cancer breakthrough? tumor slices could reveal best drug for each patient
NCT ID NCT06065358
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether thin slices of ovarian tumors, kept alive in the lab, can predict how a patient will respond to chemotherapy. Researchers will take tumor samples from 48 women with advanced ovarian cancer during surgery. They will then expose the slices to different drugs and compare the lab results to how the patients actually respond to treatment. If the method works, it could lead to personalized drug testing for ovarian cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this method could help doctors quickly choose the most effective chemotherapy for each ovarian cancer patient, improving treatment outcomes.
What could go wrong
This is a small, early feasibility study with only 48 participants. The lab test may not accurately predict real patient responses, and results may not apply to all ovarian cancer types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Italy